We have performed a Western blot analysis on protein lysates extracted from the patient's (individual C.V-1 in Figure 1 ) and a control subject's lymphoblastoid cell lines using anti-NDE1 antibody (ProteinTech Group, 10233-1-AP), the epitope of which is not preserved in the mutant peptide.
Anti-GAPDH (Santa Cruz Biotechnology, sc-25778) antibody was used as a loading control. As expected NDE1 was detected in the control as evidenced by a 38kDa band in the blot. Interestingly, a same sized band (38KDa) was also detected in the patient (C.V-1), albeit fainter, with no evidence of an additional band at about 16kDa, which would be indicative of the predicted mutant novel peptide. In the light of the mRNA sequencing from the patient's cell line, which showed the presence of only the mutant RNA, we assume that the NDE1 detection in the patient (C.V-1) can be attributable to the crossreactivity of the anti-NDE1 antibody with NDEL1, which shares more than 60% identity and 75% similarity with NDE1. Alternatively, a splice isoform excluding the affected exon and thus escaping the effect of the splice site mutation could have been detected in the patient (C.V-1). Indeed, NDE1
demonstrates alternative splicing and there is evidence of presence of ESTs such as BG760232.1 or BG744425.1 which may account for shorter NDE1 isoforms.
A. NDE1 antibody at a dilution of 1/500, 2 minutes film exposure. Figure 5A and 5B, and accessory images.
A. NDE1 expression in a CS23 human embryo head. In situ hybridization using a riboprobe to NDE1 was performed on a sagittal section of a human embryo. Darker red staining shows expression. The upper image was generated using an antisense riboprobe and shows NDE1 expression. The lower image was generated using the sense riboprobe, and should be almost blank, and acts as a control. 
